Understanding the investment opportunity
Opportunity Health develops Yarnasa, an automatic and self-applicable medical device that allows fast and safe action against choking. This problem is one of the main causes of accidental death: in Spain, 3,500 people die every year from this cause, which is equivalent to 10 deaths per day. The incidence of choking is three times higher than that of traffic accidents, highlighting the urgent need for effective solutions such as Yarnasa.
.PNG)
Yarnasa is protected by a pending European patent (EP25382176), which protects the entire activation and operation system, including the multi-stage vacuum ejector, dual activation (actuator + trigger), intermediate chamber, release valve, and the entire system that enables automatic and safe suction application. It also covers ergonomic design, vacuum control based on the patient, and safety measures against leaks or accidental activations.
.png)
Yarnasa is protected by a pending European patent (EP25382176) that covers the complete activation and operation system, including the multi-stage vacuum ejector, dual activation (actuator + trigger), intermediate chamber, release valve, patient-adapted vacuum control, ergonomic design, and safety measures against leaks or accidental activations. The project has a tested functional prototype and is in the validation phase, having carried out tests with the University of Navarra (LABIM) and working with them and with the Health Research Institute of Santiago de Compostela (IDIS) to prepare the preclinical trials required for CE marking.
The founding team has over 30 years of combined experience in entrepreneurship, product development and innovation, healthcare regulation, industrial design, mechanical engineering, and financial management.
The business model combines a B2B approach: Opportunity Health positions itself as the manufacturer for regulatory and intellectual property purposes, with outsourced production. The design team works closely on prototyping and manufacturing vision, focusing from the outset on industrialization to optimize the product and avoid scaling issues. Distribution is planned through agreements with strategic industry players, which will allow rapid access to the institutional channel (nursing homes, transportation, catering, social and healthcare centers, and emergency services).
In parallel with validation and market entry, Opportunity Health maintains an active strategy of identifying potential strategic buyers in the medical device sector, with the aim of structuring an exit after obtaining CE marking. Since tests are carried out through simulations and it is not possible to induce real choking, the validation process could be faster and simpler, relying on literature and controlled trials. This combination of commercial traction and a consolidated distribution network seeks to maximize profitability for investors.
.PNG)
INVESTMENT STAGE
MARKET
- medtech
- salud
- tecnología-sanitaria
- (+2)
OFFICIAL WEBPAGE
Opportunity Health Team
CEO
Germán Alejandro Sánchez Martín
CEO
CTO
Nicolás López de Aguileta Castaño
CTO
Iñigo Almazán Tife
Ingeniero de Diseño Industrial
Ignacio Menéndez-Manjón Tartiere
CFO As a Service (Koala Smart Business)
EASO VENTURES
INVESTOR
Sodena
INVESTOR
BerriUp
ACCELERATOR
CEIN
INCUBATOR
Silo Acelera Bio
ACCELERATOR
Startup Ready
ACCELERATOR
Reasons to invest View more data
Critical problem and compelling figures
- Each year more than 3,500 people die from choking in Spain alone, which equals 10 deaths per day. This incidence is three times higher than that of traffic accidents.
Unique device
- Yarnasa is an automatic and self-applicable anti-choking device, protected by a pending European patent. It requires no strength or training: just place it and pull a trigger. It is one of the few in its category designed to meet European standards (CE marking in preparation).
Scientific and technical validation
- In validation phase with the University of Navarra (LABIM), a benchmark in applied biomedical engineering, and with the Health Research Institute of Santiago de Compostela (IDIS), a center with extensive experience in clinical research. Both provide methodological rigor, technical knowledge, and proven experience in the validation of healthcare technologies and preparation of preclinical trials for CE marking.
Market validation and institutional support
- Letters of interest and support received from key entities such as Acuna Gestión Asistencial, CEIN, Nafarco, Navarra Health Cluster, the University of Navarra, and Colegio El Catón, recognizing the innovative nature of Yarnasa and its potential impact on social-health and educational safety.
Proven B2B model
Opportunity Health acts as manufacturer for regulatory and industrial property purposes, with manufacturing outsourced to an ISO 13485 certified partner. Model comparable to that of defibrillators (AEDs).
Clear target market
- Nursing homes, social and healthcare centers, transport, catering and emergency services; estimated B2B volume in Spain (SOM) ≈ €221M, within a European market (SAM) ≈ €2.21B and global market (TAM) ≈ €8.84B.
Recurring revenue generation
- Proven and scalable B2B leasing model: monthly fee per device that includes maintenance, mandatory certification and single-use consumables, replicating the success of the defibrillator (AED) market.
Institutional investor support
- Easo Ventures and Sodena —committed as reference investors, with follow-on option—. Both have experience in health (medtech, biotech and pharma) and provide validation, network in the healthcare ecosystem (clinicians, industry and administration), co-investment and financial support capacity for later stages.
Defined exit plan
- Active strategy of identifying strategic buyers for an exit after CE marking, maximizing return for investors.
Team with extensive experience
Team with extensive experience in entrepreneurship, product innovation, design, regulatory affairs and management, reinforced with strategic partners and technical advisors.
Recognitions and awards
- Project awarded and supported in acceleration and validation programs at regional and national level.
- CEIN Health 2023 – Best Innovative Project in Medical Devices.
- Award for Autonomous Work in Innovation 2024 (Baluarte).
- 3rd place – Innovator’s Pitch Challenge, RESI Europe 2025 (Barcelona).
- Social Enterprise Award 2025 – Best Innovation in Health Advancement.
- <a href="http
Who is the reference investor?
EASO VENTURES
INVESTOR
About EASO VENTURES
Easo Ventures es una sociedad de capital riesgo vasca y privada, creada para acompañar a personas y empresas con proyectos de crecimiento sólido. Nuestro compromiso va más allá de la inversión: ofrecemos asesoramiento estratégico y la experiencia de un equipo de mentores de primer nivel que colaboran estrechamente con nosotros. Invertimos en proyectos con aportaciones que van desde 100.000 € hasta 1 millón de euros.- Investing in startups: Since 2018
- Euros invested: +€20M
- Investments:+70
- Exits:4
It has also invested in...
Live
Chat
You need to be registered to view the content
This content is confidential and you must be registered with Startupxplore in order to access it.
Register meOpportunity analysis Last update Oct 7, 2025 10:28:41 AM
You need to be registered to view the content
This content is confidential and you must be registered with Startupxplore in order to access it.
Register meInvestor questions
The regulations governing Startupxplore's activity require that no investor is in possession of more information than the rest. Therefore, this section will provide answers to any questions asked by an investor about the opportunity.
If you have any doubts or questions about the startup, the process or any other aspect please write to us at coinversion@startupxplore.com
You need to be registered to view the content
This content is confidential and you must be registered with Startupxplore in order to access it.
Register meDocumentation
You need to be registered to view the content
This content is confidential and you must be registered with Startupxplore in order to access it.
Register me